Prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis with rectal non-steroidal anti-inflammatory drugs

키워드

참고문헌 (58)

1. Freeman ML, "Complications of endoscopic biliary sphincterotomy", N Engl J Med, 335, pp.909~918 (1996)
2. Freeman ML, "Prevention of post-ERCP pancreatitis : a comprehensive review", Gastrointest Endosc, 59, pp.845~864 (2004)
3. Thiruvengadam NR, "Rectal indomethacin reduces pancreatitis in high- and low-risk patients undergoing endoscopic retrograde cholangiopancreatography", Gastroenterology, 151, pp.288~297 (2016)
4. Luo H, "Routine pre-procedural rectal indometacin versus selective post-procedural rectal indometacin to prevent pancreatitis in patients undergoing endoscopic retrograde cholangiopancreatography : a multicentre, single-blinded, randomised controlled trial", Lancet, 387, pp.2293~2301 (2016)
5. Elmunzer BJ, "A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis", N Engl J Med, 366, pp.1414~1422 (2012)
6. Andriulli A, "Incidence rates of post-ERCP complications : a systematic survey of prospective studies", Am J Gastroenterol, 102, pp.1781~1788 (2007)
7. Kochar B, "Incidence, severity, and mortality of post-ERCP pancreatitis : a systematic review by using randomized, controlled trials", Gastrointest Endosc, 81, pp.143~149 (2015)
8. Brust R, "Pancreatic injury following ERCP. Failure of prophylactic benefit of Trasylol", Gastrointest Endosc, 24, pp.77~79 (1977)
9. Odes HS, "Effect of calcitonin on the serum amylase levels after endoscopic retrograde cholangiopancreatography", Digestion, 16, pp.180~184 (1977)
10. Murray B, "Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography", Gastroenterology, 124, pp.1786~1791 (2003)
11. Sotoudehmanesh R, "Indomethacin may reduce the incidence and severity of acute pancreatitis after ERCP", Am J Gastroenterol, 102, pp.978~983 (2007)
12. "Rev Esp Enferm Dig", 2007, 330~336
13. Khoshbaten M, "Role of diclofenac in reducing post-endoscopic retrograde cholangiopancreatography pancreatitis", J Gastroenterol Hepatol, 23(7 Pt 2), pp.e11~e16 (2008)
14. Murray WR, "Reducing the incidence and severity of post ERCP pancreatitis", Scand J Surg, 94, pp.112~116 (2005)
15. Hla T, "Human cyclooxygenase-2 cDNA", Proc Natl Acad Sci U S A, 89, pp.7384~7388 (1992)
16. Agro A, "Prostaglandin E2 enhances interleukin 8 (IL-8) and IL-6 but inhibits GMCSF production by IL-1 stimulated human synovial fibroblasts in vitro", J Rheumatol, 23, pp.862~868 (1996)
17. Crofford LJ, "Cyclooxygenase-1 and-2 expression in rheumatoid synovial tissues : effects of interleukin-1 beta, phorbol ester, and corticosteroids", J Clin Invest, 93, pp.1095~1101 (1994)
18. Huang ZF, "Differential regulation of cyclooxygenase-2 (COX-2) mRNA stability by interleukin-1beta (IL-1 beta) and tumor necrosis factor-alpha (TNF-alpha)in human in vitro differentiated macrophages", Biochem Pharmacol, 59, pp.187~194 (2000)
19. Ethridge RT, "Cyclooxygenase-2 gene disruption attenuates the severity of acute pancreatitis and pancreatitis-associated lung injury", Gastroenterology, 123, pp.1311~1322 (2002)
20. Chan YC, "Acute pancreatitis : animal models and recent advances in basic research", Pancreas, 34, pp.1~14 (2007)
21. Masferrer JL, "Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic", Proc Natl Acad Sci U S A, 91, pp.3228~3232 (1994)
22. Song AM, "Inhibition of cyclooxygenase-2 ameliorates the severity of pancreatitis and associated lung injury", Am J Physiol Gastrointest Liver Physiol, 283, pp.G1166~G1174 (2002)
23. Foitzik T, "Selective inhibition of cyclooxygenase-2 (COX-2) reduces prostaglandin E2 production and attenuates systemic disease sequelae in experimental pancreatitis", Hepatogastroenterology, 50, pp.1159~1162 (2003)
24. Slogoff MI, "COX-2 inhibition results in alterations in nuclear factor(NF)-kappaB activation but not cytokine production in acute pancreatitis", J Gastrointest Surg, 8, pp.511~519 (2004)
25. Sorensen HT, "Newer cyclo-oxygenase-2 selective inhibitors, other non-steroidal anti-inflammatory drugs and the risk of acute pancreatitis", Aliment Pharmacol Ther, 24, pp.111~116 (2006)
26. Hung SC, "Use of celecoxib correlates with increased relative risk of acute pancreatitis : a case-control study in Taiwan", Am J Gastroenterol, 110, pp.1490~1496 (2015)
27. Lucas S, "The pharmacology of indomethacin", Headache, 56, pp.436~446 (2016)
28. Turakka H, "Biopharmaceutical assessment of phenylbutazone and indomethacin preparations", Ann Clin Res, 6(Suppl 11), pp.34~43 (1974)
29. Riess W, "Pharmacokinetics and metabolism of the anti-inflammatory agent Voltaren", Scand J Rheumatol Suppl, 22, pp.17~29 (1978)
30. Wallusch WW, "Comparative bioavailability : influence of various diets on the bioavailability of indomethacin", Int J Clin Pharmacol Biopharm, 16, pp.40~44 (1978)
31. Jensen KM, "Bioavailability of indomethacin after intramuscular injection and rectal administration of solution and suppositories", Acta Pharmacol Toxicol (Copenh), 57, pp.322~327 (1985)
32. Cheon YK, "Efficacy of diclofenac in the prevention of post-ERCP pancreatitis in predominantly high-risk patients: a randomized double-blind prospective trial", Gastrointest Endosc, 66, pp.1126~1132 (2007)
33. 이태윤, "Oral udenafil and aceclofenac for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients: a randomized multicenter study", The Korean Journal of Internal Medicine, 30(5), pp.602~609 (2015), 대한내과학회[DOI]
34. Park SW, "Intramuscular diclofenac for the prevention of post-ERCP pancreatitis : a randomized trial", Endoscopy, 47, pp.33~39 (2015)
35. Willis JV, "The pharmacokinetics of diclofenac sodium following intravenous and oral administration", Eur J Clin Pharmacol, 16, pp.405~410 (1979)
36. Rustagi T, "Factors affecting the efficacy of nonsteroidal anti-inflammatory drugs in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis : a systematic review and meta-analysis", Pancreas, 44, pp.859~867 (2015)
37. Patai A, "Indomethacin and diclofenac in the prevention of post-ERCP pancreatitis : a systematic review and meta-analysis of prospective controlled trials", Gastrointest Endosc, 85, pp.1144~1156 (2017)
38. Lai JH, "A randomized trial comparing the efficacy of single-dose and double-dose administration of rectal indomethacin in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis", Medicine (Baltimore), 98, pp.e15742~ (2019)
39. Lyu Y, "What is impact of nonsteroidal anti-inflammatory drugs in the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis : a meta-analysis of randomized controlled trials", BMC Gastroenterol, 18, pp.106~ (2018)
40. Levenick JM, "Rectal indomethacin does not prevent post-ERCP pancreatitis in consecutive patients", Gastroenterology, 150, pp.911~917 (2016)
41. Inamdar S, "Rectal indomethacin is protective against post-ERCP pancreatitis in high-risk patients but not average-risk patients : a systematic review and meta-analysis", Gastrointest Endosc, 85, pp.67~75 (2017)
42. Otsuka T, "Low-dose rectal diclofenac for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis : a randomized controlled trial", J Gastroenterol, 47, pp.912~917 (2012)
43. Fogel EL, "Rectal indometacin dose escalation for prevention of pancreatitis after endoscopic retrograde cholangiopancreatography in high-risk patients : a double-blind, randomised controlled trial", Lancet Gastroenterol Hepatol, 5, pp.132~141 (2020)
44. Hosseini M, "Prophylactic effect of rectal indomethacin administration, with and without intravenous hydration, on development of endoscopic retrograde cholangiopancreatography pancreatitis episodes: a randomized clinical trial", Arch Iran Med, 19, pp.538~543 (2016)
45. Mok SRS, "Lactated Ringer’s solution in combination with rectal indomethacin for prevention of post-ERCP pancreatitis and readmission : a prospective randomized, double-blinded, placebo-controlled trial", Gastrointest Endosc, 85, pp.1005~1013 (2017)
46. Hajalikhani M, "Combination of diclofenac and aggressive hydration for the prevention of post-ERCP pancreatitis", Gastroenterol Hepatol Bed Bench, 11, pp.319~324 (2018)
47. Katsinelos P, "Combination of diclofenac plus somatostatin in the prevention of post-ERCP pancreatitis : a randomized, double-blind, placebo-controlled trial", Endoscopy, 44, pp.53~59 (2012)
48. Sotoudehmanesh R, "A randomized trial of rectal indomethacin and sublingual nitrates to prevent post-ERCP pancreatitis", Am J Gastroenterol, 109, pp.903~909 (2014)
49. Tomoda T, "Combination of diclofenac and sublingual nitrates is superior to diclofenac alone in preventing pancreatitis after endoscopic retrograde cholangiopancreatography", Gastroenterology, 156, pp.1753~1760 (2019)
50. Hatami B, "Epinephrine in the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis : a preliminary study", Case Rep Gastroenterol, 12, pp.125~136 (2018)
51. Kamal A, "A randomized trial of topical epinephrine and rectal indomethacin for preventing post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients", Am J Gastroenterol, 114, pp.339~347 (2019)
52. Luo H, "Rectal indomethacin and spraying of duodenal papilla with epinephrine increases risk of pancreatitis following endoscopic retrograde cholangiopancreatography", Clin Gastroenterol Hepatol, 17, pp.1597~1606 (2019)
53. Akshintala VS, "Systematic review with network meta-analysis : pharmacological prophylaxis against post-ERCP pancreatitis", Aliment Pharmacol Ther, 38, pp.1325~1337 (2013)
54. Gromski MA, "End of the road for epinephrine spraying of the papilla to prevent post-endoscopic retrograde cholangiopancreatography pancreatitis", Clin Gastroenterol Hepatol, 17, pp.1446~1447 (2019)
55. Choudhary A, "Pancreatic stents for prophylaxis against post-ERCP pancreatitis : a meta-analysis and systematic review", Gastrointest Endosc, 73, pp.275~282 (2011)
56. Mazaki T, "Prophylactic pancreatic stent placement and post-ERCP pancreatitis : an updated meta-analysis", J Gastroenterol, 49, pp.343~355 (2014)
57. Akbar A, "Rectal nonsteroidal anti-inflammatory drugs are superior to pancreatic duct stents in preventing pancreatitis after endoscopic retrograde cholangiopancreatography : a network meta-analysis", Clin Gastroenterol Hepatol, 11, pp.778~783 (2013)
58. Elmunzer BJ, "Rectal indomethacin alone versus indomethacin and prophylactic pancreatic stent placement for preventing pancreatitis after ERCP : study protocol for a randomized controlled trial", Trials, 17, pp.120~ (2016)

관련 논문AI추천